Hepatitis C Virus (HCV) Gensosure® NS3/4A Provides Comprehensive Resistance Data for HCV Protease Inhibitors

  • Analyzes the genetic sequence for the nonstructural proteins NS3 and NS4A of HCV genotypes 1a and 1b
  • Detects mutations in NS3 and NS4A and identifies drug-resistant variants for protease inhibitors grazoprevir, paritaprevir​, simeprevir. glecaprevir and voxilaprevir.
  • Uses a next generation sequencing (NGS) platform to detect minor variants at levels as low as 10% of the total population.
Test Name Hepatitis C Virus (HCV) GenoSure® NS3/4A
LabCorp Test Number 550540
Limitation For patients with HCV genotype (subtype) 1a or 1b and a viral load ≥ 2000 IU/mL
Specimen Collection 3 mL plasma, EDTA or PPT tube, shipped frozen
Turnaround Time 7 to 10 days

Pharmaceutical companies are using our HCV genotypic and phenotypic resistance assays to support all phases of research and clinical development for several new HCV compounds. As more new compounds reach the clinic, Monogram's assays will continue to provide useful information for patient management. For more information about our full line of HIV, HCV, or pharmaceutical services, visit our Pharma Collaborations page.

HCVGenoSure